223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide

被引：1

作者：

Carles, J. ^{[1
,2
]}

Alonso, T. ^{[3
]}

Mellado Gonzalez, B. ^{[4
,5
]}

Mendez Vidal, M. J. ^{[6
,7
]}

Vazquez Estevez, S. ^{[8
]}

Gonzalez del Alba, A. ^{[9
]}

Piulats, J. M. ^{[10
]}

Borrega Garcia, P. ^{[11
]}

Gallardo, E. ^{[12
,13
,14
]}

Morales Barrera, R. ^{[15
,16
]}

Paredes, P. ^{[17
,18
]}

Reig, O. ^{[17
,18
]}

Garcias de Espana, C. ^{[19
]}

Collado, R. ^{[20
]}

Bonfill, T. ^{[12
,13
,14
]}

Suarez, C. ^{[21
,22
]}

Malfettone, A. ^{[23
]}

Garde, J. ^{[23
]}

机构：

[1] Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain

[2] Med Scientia Innovat Res MedSIR, Barcelona, Spain

[3] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain

[4] Hosp Clin Barcelona, Oncol Serv, Barcelona, Spain

[5] Univ Barcelona, Barcelona, Spain

[6] Maimonides Inst Biomed Res Cordoba IMIBIC, Med Oncol, Cordoba, Spain

[7] Reina Sofia Univ Hosp HURS, Dept Med Oncol, Cordoba, Spain

[8] Lucus Augusti Univ Hosp, Med Oncol, Lugo, Spain

[9] Puerta de Hierro Majadahonda Univ Hosp, Med Oncol, Madrid, Spain

[10] Catalan Inst Oncol, Med Oncol, Barcelona, Spain

[11] San Pedro de Alcantara Hosp, Med Oncol, Caceres, Spain

[12] Parc Tauli Univ Hosp, Med Oncol Dept, Barcelona, Spain

[13] Parc Tauli Inst Res & Innovat I3PT, Barcelona, Spain

[14] Barcelona Autonomous Univ, Barcelona, Spain

[15] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain

[16] Vall dHebron Inst Oncol, Barcelona, Spain

[17] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain

[18] Univ Barcelona, Barcelona, Spain

[19] Son Espases Univ Hosp, Med Oncol, Mallorca, Spain

[20] Complejo Hosp Caceres, Med Oncol, Caceres, Spain

[21] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[22] Vall dHebron Inst Oncol, Barcelona, Spain

[23] Med Scientia Innovat Res MedSIR, Med Dept, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.898

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

639P

引用

页码：S525 / S526

页数：2

共 50 条

[1] Combination treatment with radium-223 (223Ra) and enzalutamide (enza) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the REASSURE study
Tombal, B.
Goebell, P. J.
Shore, N. D.
George, D. J.
Pinto, A.
Sartor, O.
Meltzer, J.
Verholen, F.
Schmall, A.
Saad, F.
ANNALS OF ONCOLOGY, 2023, 34 : S984 - S984
[2] Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
Tseng, Chi-Shin
Yang, Jui-Han
Huang, Shi-Wei
Wang, Yu-Jen
Chen, Chung-Hsin
Pu, Yeong-Shiau
Cheng, Jason Chia-Hsien
Huang, Chao-Yuan
BMC CANCER, 2023, 23 (01)
[3] Survival outcomes and prognostic factors for first-line abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer
Chi-Shin Tseng
Jui-Han Yang
Shi-Wei Huang
Yu-Jen Wang
Chung-Hsin Chen
Yeong-Shiau Pu
Jason Chia-Hsien Cheng
Chao-Yuan Huang
BMC Cancer, 23
[4] Clinical activity of enzalutamide against metastatic castration-resistant prostate cancer (mCRPC) in patients who have progressed on abiraterone acetate: The Princess Margaret experience.
Vera-Badillo, Francisco Emilio
Leibowitz-Amit, Raya
Templeton, Arnoud
Seah, Jo-An
Sridhar, Srikala S.
Knox, Jennifer J.
Tannock, Ian
Joshua, Anthony Michael
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
[5] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Petrylak, D. P.
Vaishampayan, U. N.
Patel, K. R.
Higano, C. S.
Albany, C.
Dawson, N. A.
Mehlhaff, B. A.
Quinn, D. I.
Nordquist, L. T.
Wagner, V. J.
Shen, J.
Trandafir, L.
Sartor, O.
ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
[6] Abiraterone or Enzalutamide for Patients With Metastatic Castration-Resistant Prostate Cancer
La, Jennifer
Wang, Lin
Corrigan, June K.
Lang, Deborah
Lee, Michelle H.
Do, Nhan V.
Brophy, Mary T.
Paller, Channing J.
Fillmore, Nathanael R.
JAMA NETWORK OPEN, 2024, 7 (08)
[7] Enzalutamide in Combination with Abiraterone Acetate in Bone Metastatic Castration-resistant Prostate Cancer Patients
Efstathiou, Eleni
Titus, Mark
Wen, Sijin
Troncoso, Patricia
Hoang, Anh
Corn, Paul
Prokhorova, Ina
Araujo, John
Dmuchowski, Carl
Melhem-Bertrandt, Amal
Patil, Shiva
Logothetis, Christopher J.
EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 119 - 127
[8] Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC).
Briones, Carvajal
Juan, Rodrigo
Naimi, Mahdi Farzad
Zhang Liying
Emmenegger, Urban
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[9] Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) sequentially treated with abiraterone acetate (AA) and radium-223 (RA223).
Caffo, Orazio
Frantellizzi, Viviana
Tucci, Marcello
Galli, Luca
Monari, Fabio
Baldari, Sergio
Masini, Cristina
Bortolus, Roberto
Facchini, Gaetano
Alongi, Pierpaolo
Zichi, Clizia
Biasco, Elisa
Fanti, Stefano
Pignata, Salvatore
Filice, Angelina
Borsatti, Eugenio
Rossetti, Sabrina
Spada, Massimiliano
Cortesi, Enrico
De Vincentis, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial
Carles, Joan
Alonso-Gordoa, Teresa
Mellado, Begona
Mendez-Vidal, Maria J.
Vazquez, Sergio
Gonzalez-del-Alba, Aranzazu
Piulats, Josep M.
Borrega, Pablo
Gallardo, Enrique
Morales-Barrera, Rafael
Paredes, Pilar
Reig, Oscar
Garcias de Espana, Carmen
Collado, Ricardo
Bonfill, Teresa
Suarez, Cristina
Sampayo-Cordero, Miguel
Malfettone, Andrea
Garde, Javier
EUROPEAN JOURNAL OF CANCER, 2022, 173 : 317 - 326

← 1 2 3 4 5 →